Portfolio data

Browse all portfolio data news

    Latest portfolio data news

    Show news from

    Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

    New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

    Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

    Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposiumTM

    Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting

    Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results

    Load more

    Search